From Digital Age to Nano Age. WorldWide.

Tag: autism

Robotic Automations

EarliTec Diagnostics raises $21.5M to help diagnose autism earlier | TechCrunch


One in 36 children in the U.S. has autism, according to the CDC. Research shows that the earlier a child gets diagnosed, the better their developmental outcome will be. EarliTec Diagnostics just raised fresh capital to expand its system that helps clinicians diagnose children as young as 16 months old.

The Atlanta-based startup’s FDA-authorized approach involves a child watching short videos and social interactions on a screen for 12 minutes while the device, using AI, tracks the child’s eye movements. According to EarliTec, children with autism won’t focus on the video the same way that kids without autism will.

The startup raised a $21.5 million Series B round co-led by Nexus NeuroTech Ventures, a venture firm focused on backing companies creating solutions for brain disorders, and Venture Investors, a Midwestern venture fund that invests in healthcare companies. The startup’s tech is currently used by eight clinicians across six states in the U.S.

EarliTec Diagnostics CEO Tom Ressemann told TechCrunch that traditional autism diagnoses involve three- or four-hour assessments that can have lengthy waitlists. EarliTec’s 12-minute test is designed to help clinicians get to a diagnosis faster, which helps them work with more children.

“You have to be able to work into their current workflow,” Ressemann said. “So with a test like ours that is flexible where you access it, it could be at the child’s home, it could be at a clinic or a school, it’s a tablet, we can work into most workflows. A quicker diagnosis is better for the child and the parent.”

The company plans to use the money to continue to expand its commercialization, Ressemann said. EarliTec currently works with children aged 16 months to 30 months and plans to funnel some of its fresh capital into research that could help the company expand the age group the system can diagnose. It also hopes the capital can help improve assessment and treatment options.

Ressemann, who was CEO at several other medical device startups prior to EarliTec, including Amphora Medical and Entellus Medical, said this fundraise was the most challenging and yet the most rewarding. He said despite the prevalence of autism in the U.S., it’s still a hard area in which to fundraise because only certain investors are interested in the space. But that’s starting to change.

The reason this deal intrigued me so much was that there seems to be growing momentum and interest in the autism-focused healthcare space from VCs; prior to 2021, this was more rare.

This week, the Autism Impact Fund closed a $60 million fund, 20% higher than its $50 million target. The Autism Impact Fund isn’t the only firm investing in the space, either. Divergent Ventures raised a $10 million fund in 2021 that focuses on early-stage companies across the neurodiversity space. EarliTec backer Nexus NeuroTech Ventures was just launched in 2023.

Several startups in the space have raised notable rounds, too. Cortica, which does diagnoses and treatment plans, has raised more than $175 million in venture funding from firms such as CVS Health Ventures and .406 Ventures. Forta, family-focused autism therapy, has raised more than $55 million from backers, including Insight Partners and Alumni Fund. Opya, a digital therapy platform for autism, has raised more than $19 million from backers, including SoftBank’s Open Opportunity Fund.

Ressemann said the breadth of diagnosis and assessment tools and treatments has changed rapidly since he and his wife went through the diagnosis and treatment process years ago with their now 27-year-old son.

While it’s been great to see startups and venture backing treatments and tools to support children with autism, you always wonder why investors have gotten interested in backing solutions now — or why they weren’t before. I asked Ressemann what he thought, and he said that awareness of the condition’s prevalence has made a big difference.

“Just a few years ago it was considered to be one in a 1,000 children. It’s now one in 36,” Ressemann said. “That’s awareness.”

This makes a lot of sense. My mind had always considered the goal of awareness campaigns to be that more people without the condition understood its prevalence, but I hadn’t considered that more information out there would also help lead to more diagnoses, giving a more accurate picture of just how many people this actually affects. Having those numbers in hand helps investors see the total addressable market and opportunity.

“There is an attraction to the size and the magnitude of the problem,” Ressemann said regarding recent VC interest. “Where there is a large unmet need there is often interest to get into that.”

Hopefully investors stay interested because more money going into startups like this that can help children with developmental delays and disorders, and that can make VCs money, seems like a great strategy to make a return while directly improving people’s lives.


Software Development in Sri Lanka

Robotic Automations

Autism Impact Fund closes $60M first fund and broadens its scope | TechCrunch


Millions of people around the world are affected by autism spectrum disorder (ASD). Both as kids and later in life, these individuals and their families need better detection, treatment and support solutions that will help them live with autism. But until recently, that wasn’t a space that startups and investors ventured into.

Autism Impact Fund (AIF) was a pioneer when it emerged in 2021, three years after the son of its co-founder and managing partner, Chris Male, was diagnosed with ASD. A joint effort of Male and others, AIF strove to become “the investment and innovation arm of the autism community,” Male told TechCrunch.

Since then, startups in the neurodiversity space gathered momentum, and so did AIF, which recently closed its first fund at $60 million. As a first-of-its-kind fund, exceeding its target is no small feat, especially in an incredibly difficult environment. (The original target was $50 million.)

AIF is a VC fund, not a charity, and Male is also vocal about it. “We’ve got great collaborations with the nonprofits, with the foundations, and we are very intentional in our regard to drive returns. … We aim to deliver really strong returns while revolutionizing the status quo for autism and everything in the space through the venture capital model.”

AIF’s limited partners include Uber CEO Dara Khosrowshahi; Brian Jacobs from Emergence Capital Partners; and Bob Nelsen, a co-founder and managing director of Arch Venture Partners, who also sit on its advisory board. Male didn’t want to tell their personal stories for them, but AIF’s individual backers often have personal connections to autism.

However, institutional LPs such as investment firms Fairfield-Maxwell and Ferd also support AIF, “which obviously was very helpful to get us to that scale,” Male said. It is also one more sign of change. “The operators that are entering the space are no longer just family members wanting to help; it’s really sophisticated business operators that are seeing an opportunity to affect wholesale change, and it’s really cool.”

A broad portfolio

Some VC funds wait for a full close to start deploying capital, but not AIF. Because it needed to prove itself and its thesis, it started investing since its first close. With 12 startups in its portfolio, it will start raising its second fund in the next six to nine months, and Male already reports inbound interest.

That companies in AIF’s portfolio raised follow-on rounds from other investors is a strong validation signal. For instance, CVS Health Ventures led a $40 million Series D extension round of investment into healthcare startup Cortica in October. Other signals are harder to measure but are still important. Male told TechCrunch that AIF has strong access even to oversubscribed deals, and even when its check is not the largest, there’s a sense that it’s “a stamp of approval to the market and to the community that this is a validated, well-run entity.”

AIF still has resources in its first fund to do a “handful” more deals as well as follow-on investments. After several “strong bets,” its portfolio is giving it motive to double down. And, Male added, “there is a very high likelihood of us having exits within the next six months; so, soon, because we [starting deploying] in 2021.”

AIF’s portfolio is already quite diverse, although its website groups companies in two categories: life sciences and data- and tech-enabled services. It also goes beyond the U.S. with Germany-based consulting firm Auticon, which describes itself as an “autism-majority company,” and British telehealth platform Healios. But it will now diversify it further, and not because there isn’t enough deal flow or issues to address with autism alone.

AIF’s decision to broaden its scope has to do with autism itself, Male said.

The definition of autism is so vague and so broad that there’s really no [biologically precise] understanding of exactly what’s happening, so in order for us to help the individuals as well as the families, we have to broaden that aperture. And it’s behavioral and mental health, it’s all of those but it’s also a broader healthcare issue at lens. The societal cost is in the trillions of dollars right now, and if the rise of incidence increases at the rate it is, it’s $15 trillion societal costs. Lack of employment and being [un]able to work is factored into that. But it’s as if society is sleepwalking into this incredible crisis, for which there is no current plan.

Rising awareness

The fund will now allow itself to invest in “behavioral health data-driven platforms, innovative healthcare solutions, as well as value-based care frameworks,” and AI is “impossible to ignore,” Male said. It will also keep on investing in addressing autism comorbidities, for instance gastrointestinal issues. And then there’s the “independence bucket,” whether that’s employment, financial independence or housing.

That independence is on the list is a reminder that autism is a spectrum that needs to be addressed as such and that there is a business opportunity for startups that don’t solely focus on kids.

One startup focusing on adults, neurodiversity employment network Mentra, is backed by Sam Altman and others but not by AIF. No beef there: Mentra partnered with AIF-backed Auticon, and Male called the work they are doing “incredible.”

It’s arguably a good sign that AIF isn’t one of Mentra’s investors: The space is getting too big to find the same VC on all cap tables. It’s also global, with health tech Genial Care raising $10 million to help kids with autism and their families in Brazil.

When asked if there wasn’t some momentum about company creation in this space recently, Male laughed. Compared to five years ago, he explained, “it’s just fun to see the momentum and the shift.” As the investment side gets busier, too, there will likely be more to come.


Software Development in Sri Lanka

Back
WhatsApp
Messenger
Viber